{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:25:42Z","timestamp":1791897942618,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recently published International Consensus Classification (ICC) of myeloid neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and geneticists aimed to update the 2017 World Health Organization classification system for hematopoietic tumors. Along these lines, several important modifications were implemented in the classification of myeloproliferative neoplasms (MPNs). For chronic myeloid leukemia, <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1-<\/jats:italic>positive, the definition of accelerated and blast phase was simplified, and in the <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1-<\/jats:italic>negative MPNs, the classification was slightly updated to improve diagnostic specificity with a more detailed and better validated morphologic approach and the recommendation of more sensitive molecular techniques to capture in particular early stage diseases. In this regard, high sensitive single target (RT-qPCR, ddPCR) or multi-target next-generation sequencing assays with a minimal sensitivity of VAF 1% are now important for a proper diagnostic identification of MPN cases with low allelic frequencies at initial presentation. This review discusses the updated diagnostic criteria of MPN according to the ICC, particularly by highlighting the new concepts and how they can be applied in clinical settings to obtain an appropriate prognostic relevant diagnosis.<\/jats:p>","DOI":"10.1007\/s00428-022-03480-8","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T08:02:57Z","timestamp":1672300977000},"page":"53-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms"],"prefix":"10.1007","volume":"482","author":[{"given":"Umberto","family":"Gianelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-4840","authenticated-orcid":false,"given":"Hans Michael","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"15","key":"3480_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"2022","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022(15):1200\u20131228","journal-title":"Blood."},{"key":"3480_CR2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL et al (eds) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC"},{"key":"3480_CR3","volume-title":"Cancer facts & figures 2019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society (2019) Cancer facts & figures 2019. American Cancer Society, Atlanta"},{"key":"3480_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.12695","volume":"97","author":"N Thielen","year":"2016","unstructured":"Thielen N, Visser O, Ossenkoppele G, Janssen J (2016) Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 97:145\u2013154","journal-title":"Eur J Haematol."},{"key":"3480_CR5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/hematology.2021000240","volume":"2021","author":"J How","year":"2021","unstructured":"How J, Venkataraman V, Hobbs GS (2021) Blast and accelerated phase CML: room for improvement. Hematology Am Soc Hematol Educ Program. 2021:122\u2013128","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"3480_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12703\/r\/10-35","volume":"10","author":"R Kumar","year":"2021","unstructured":"Kumar R, Krause DS (2021) Recent advances in understanding chronic myeloid leukemia: where do we stand? Fac Rev. 10:35","journal-title":"Fac Rev."},{"key":"3480_CR7","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","volume":"12","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Rinke J, Schafer V et al (2014) Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 12:2292\u20132299","journal-title":"Leukemia."},{"key":"3480_CR8","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/cncr.31663","volume":"124","author":"JE Hidalgo-Lopez","year":"2018","unstructured":"Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE et al (2018) Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value. Cancer. 124:3849\u20133855","journal-title":"Cancer."},{"key":"3480_CR9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 376:917\u2013927","journal-title":"N Engl J Med."},{"key":"3480_CR10","first-page":"1241","volume":"14","author":"J Thiele","year":"1999","unstructured":"Thiele J, Kvasnicka HM, Fischer R (1999) Bone marrow histopathology in chronic myelogenous leukemia (CML)\u2013evaluation of distinctive features with clinical impact. Histol Histopathol 14:1241\u20131256","journal-title":"Histol Histopathol"},{"key":"3480_CR11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428190009148850","volume":"36","author":"J Thiele","year":"2000","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A et al (2000) Bone marrow features and clinical findings in chronic myeloid leukemia\u2013a comparative, multicenter, immunohistological and morphometric study on 614 patients. Leuk Lymphoma. 36:295\u2013308","journal-title":"Leuk Lymphoma."},{"key":"3480_CR12","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","volume":"92","author":"AB Raitano","year":"1995","unstructured":"Raitano AB, Halpern JR, Hambuch TM (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 92:11746\u201311750","journal-title":"Proc Natl Acad Sci U S A."},{"key":"3480_CR13","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G et al (2016) Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742\u20132750","journal-title":"Blood."},{"key":"3480_CR14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Abruzzese E, Bocchia M et al (2019) Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol 12:131","journal-title":"J Hematol Oncol"},{"key":"3480_CR15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M et al (2019) 3023 Mayo Clinic patients with mye- loproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94:599\u2013610","journal-title":"Mayo Clin Proc"},{"key":"3480_CR16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, Rumi E, Arcaini L et al (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 93:1645\u20131651","journal-title":"Haematologica."},{"key":"3480_CR17","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 117:5857\u20135859","journal-title":"Blood."},{"key":"3480_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW et al (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 168:317\u2013325","journal-title":"Ann Intern Med."},{"key":"3480_CR19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","volume":"19","author":"T Rungjirajittranon","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P et al (2019) A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 19:184","journal-title":"BMC Cancer."},{"key":"3480_CR20","first-page":"e366","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood. Cancer Journal. 5:e366","journal-title":"Cancer Journal."},{"key":"3480_CR21","doi-asserted-by":"crossref","unstructured":"Rumi, E., Boveri, E., Bellini, M., et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget . 2017;8: 101735\u2013101744.","DOI":"10.18632\/oncotarget.21594"},{"key":"3480_CR22","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:3179\u20133184","journal-title":"J Clin Oncol"},{"key":"3480_CR23","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med. 381:2135\u20132144","journal-title":"N Engl J Med."},{"key":"3480_CR24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N et al (2021) Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 96:1472\u20131480","journal-title":"Am J Hematol."},{"key":"3480_CR25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","volume":"92","author":"M Yogarajah","year":"2017","unstructured":"Yogarajah M, Tefferi A (2017) Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 92:1118\u201311128","journal-title":"Mayo Clin Proc."},{"key":"3480_CR26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B et al (2017) Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 92:885\u2013891","journal-title":"Am J Hematol."},{"key":"3480_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","volume":"4","author":"J Thiele","year":"2009","unstructured":"Thiele J, Kvasnicka HM (2009) The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 4:33\u201340","journal-title":"Curr Hematol Malig Rep."},{"key":"3480_CR28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-020-0290-9","volume":"10","author":"T Barbui","year":"2020","unstructured":"Barbui T, Thiele J, Ferrari A et al (2020) The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer J. 10:22","journal-title":"Blood Cancer J."},{"key":"3480_CR29","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, M\u00fcllauer L et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 117:5710\u20135718","journal-title":"Blood."},{"key":"3480_CR30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 95:1599\u20131613","journal-title":"Am J Hematol."},{"key":"3480_CR31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 22:1299\u20131307","journal-title":"Leukemia."},{"key":"3480_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho TL, Gangat N et al (2016) Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 91:503\u2013506","journal-title":"Am J Hematol."},{"key":"3480_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL et al (2020) Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 189:291\u2013302","journal-title":"Br J Haematol."},{"key":"3480_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y et al (2016) Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 1:21\u201330","journal-title":"Blood Adv."},{"key":"3480_CR35","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 129:3227\u20133236","journal-title":"Blood."},{"key":"3480_CR36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","volume":"30","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger H, Jeryczynski G, Gisslinger B, W\u00f6lfler A, Burgstaller S, V B-A. (2016) Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 30:1126\u20131132","journal-title":"Leukemia."},{"key":"3480_CR37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","volume":"8","author":"G Finazzi","year":"2018","unstructured":"Finazzi G, Vannucchi AM, Barbui T (2018) Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J. 8:104","journal-title":"Blood Cancer J."},{"key":"3480_CR38","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2017-04-777805","volume":"129","author":"H Gisslinger","year":"2017","unstructured":"Gisslinger H (2017) Pre-PMF emerging as important subgroup of MPN. Blood 129:3142\u20133144","journal-title":"Blood"},{"key":"3480_CR39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12185-018-2495-2","volume":"108","author":"A Kamiunten","year":"2018","unstructured":"Kamiunten A, Shide K, Kameda T et al (2018) Early\/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. Int J Hematol 108:411\u2013415","journal-title":"Int J Hematol"},{"key":"3480_CR40","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/s41408-020-00368-1","volume":"10","author":"A Carobbio","year":"2020","unstructured":"Carobbio A, Guglielmelli P, Rumi E et al (2020) A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer J. 10:e100","journal-title":"Blood Cancer J."},{"key":"3480_CR41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","volume":"25","author":"U Gianelli","year":"2012","unstructured":"Gianelli U, Vener C, Bossi A et al (2012) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 25:1193\u20131202","journal-title":"Mod Pathol."},{"key":"3480_CR42","doi-asserted-by":"crossref","first-page":"E 454-E455","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Vannucchi AM, Investigators AGIMM (2016) The prognostic impact of bone marrow fibrosis in primary myelofibrosis. Am J Hematol. 91:E 454-E455","journal-title":"Am J Hematol."},{"key":"3480_CR43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M et al (2018) Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 32:1189\u20131199","journal-title":"Leukemia."},{"key":"3480_CR44","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G et al (2013) Survival and prognosis among 1,545 patients with contemporary polycythemia vera: an international study. Leukemia. 27:1874\u20131188","journal-title":"Leukemia."},{"key":"3480_CR45","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 95:1599\u20131613","journal-title":"Am J Hematol."},{"key":"3480_CR46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.24684","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Thiele J, Gisslinger H et al (2017) Diagnostic impact of the 2016 revised WHO criteria for polycythemia vera. Am J Hematol. 92:417\u2013419","journal-title":"Am J Hematol."},{"key":"3480_CR47","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi A, Barbui T (2021) Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 35:3339\u20133351","journal-title":"Leukemia"},{"key":"3480_CR48","first-page":"317","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM (2005) Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 20:317\u2013328","journal-title":"Histol Histopathol."},{"key":"3480_CR49","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2021) Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 35:3339\u20133351","journal-title":"Leukemia."},{"key":"3480_CR50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.14798","volume":"182","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Hanson CA et al (2017) Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol. 182:437\u2013440","journal-title":"Br J Haematol."},{"key":"3480_CR51","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24:1574\u20131579","journal-title":"Leukemia"},{"key":"3480_CR52","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","volume":"103","author":"B Mora","year":"2018","unstructured":"Mora B, Giorgino T, Guglielmelli P et al (2018) Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 103:e392\u2013e394","journal-title":"Haematologica."},{"key":"3480_CR53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","volume":"39","author":"U Gianelli","year":"2015","unstructured":"Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, Moro A, Savi F, Castelli R, Brambilla C et al (2015) Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk. Res. 39:525\u2013529","journal-title":"Leuk. Res."},{"key":"3480_CR54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/modpathol.2016.182","volume":"30","author":"U Gianelli","year":"2017","unstructured":"Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu Y-C, Augello C, Bonometti A, Fiori S, Orofino N et al (2017) The myeloproliferative neoplasms, unclassifiable: Clinical and pathological considerations. Mod. Pathol. 30:169\u2013179","journal-title":"Mod. Pathol."},{"key":"3480_CR55","doi-asserted-by":"crossref","first-page":"E48\u2013E51.3","DOI":"10.1002\/ajh.24657","volume":"92","author":"A Iurlo","year":"2017","unstructured":"Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A (2017) Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: comparison with the 2008 version. Am. J. Hematol. 92:E48\u2013E51.3","journal-title":"Am. J. Hematol."},{"key":"3480_CR56","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.17375","volume":"193","author":"P Deschamps","year":"2021","unstructured":"Deschamps P, Moonim M, Radia D, Curto-Garcia N, Woodley C, Bassiony S, O\u2019Sullivan J, Harrington P, Raj K, Francis Y et al (2021) Clinicopathological characterization of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre. Br. J. Haematol. 193:792\u2013797","journal-title":"Br. J. Haematol."},{"key":"3480_CR57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","volume":"95","author":"N Szuber","year":"2020","unstructured":"Szuber N, Elliott M, Tefferi A (2020 Feb) Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. Am J Hematol. 95:212\u2013224","journal-title":"Am J Hematol."},{"key":"3480_CR58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","volume":"19","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A (2005) WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 19:313\u2013317","journal-title":"Leukemia."},{"key":"3480_CR59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2005.07.012","volume":"19","author":"MA Elliott","year":"2006","unstructured":"Elliott MA (2006) Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol. 19:571\u2013593","journal-title":"Best Pract Res Clin Haematol."},{"key":"3480_CR60","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","volume":"90","author":"MA Elliott","year":"2015","unstructured":"Elliott MA, Pardanani A, Hanson CA et al (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol. 90:653\u2013656","journal-title":"Am J Hematol."},{"key":"3480_CR61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-018-0058-7","volume":"8","author":"N Szuber","year":"2018","unstructured":"Szuber N, Finke CM, Lasho TL et al (2018) CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer J. 8:21","journal-title":"Blood Cancer J."},{"key":"3480_CR62","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","volume":"30","author":"A Pardanani","year":"2016","unstructured":"Pardanani A, Lasho T, Wassie E et al (2016) Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 30:1924\u20131926","journal-title":"Leukemia."},{"key":"3480_CR63","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","volume":"29","author":"SA Wang","year":"2016","unstructured":"Wang SA, Tam W, Tsai AG et al (2016) Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 29:854\u2013864","journal-title":"Mod Pathol."},{"key":"3480_CR64","doi-asserted-by":"crossref","first-page":"e0185602","DOI":"10.1371\/journal.pone.0185602","volume":"12","author":"JS Lee","year":"2017","unstructured":"Lee JS, Seo H, Im K et al (2017) Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing. PLoS One. 12:e0185602","journal-title":"PLoS One."}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03480-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:24:03Z","timestamp":1674847443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3480"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03480-8","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}